DexCom Extends Losses Amid Leadership Change Amid Q2 Revenue Growth

DexCom (DXCM) shares fell 3.82% to $76.25 on Monday, extending losses for the fifth straight day. The company named Jake Leach as its new CEO, effective January 1, 2026. Despite the leadership change, DexCom's Q2 net income grew 25% to $179.8 million, and revenues increased 16% to $1.16 billion year-over-year.

DexCom (DXCM) shares fell 3.82% to $76.25 on Monday, extending their losses for the fifth consecutive day. The decline came despite the company reporting strong quarterly results, with net income growing 25% to $179.8 million and revenues increasing 16% to $1.16 billion year-over-year [2].

The sell-off was sparked by the announcement of a leadership change at the company. DexCom named Jake Leach as its new CEO, effective January 1, 2026. Leach will also serve as the current president and chief operating officer, while incumbent CEO Kevin Sayer will remain executive chairman of the board during the transition period [2].

Despite the leadership change, investors remain cautious. Analyst ratings for DexCom indicate an overwhelming preference for the stock, with a consensus rating of "Buy" and target prices ranging from $89.00 to $106.00 [1]. Institutional investors have also shown confidence in the company, with several increasing their stakes in the first quarter [1].

References:
[1] https://www.marketbeat.com/instant-alerts/filing-dexcom-inc-nasdaqdxcm-shares-acquired-by-geneva-capital-management-llc-2025-08-04/
[2] https://finance.yahoo.com/news/dexcom-dxcm-extends-losses-day-170656165.html